14 January 2025
In this recent preprint, researchers from the VU, AUMC, and QVQ, use single-domain antibodies (sdAbs) to modulate the chemokine receptor CXCR4.
Mobach and Bergkamp et al utilize the sdAb VUN401, which disrupts clusters of CXCR4 on lymphoma cells. This monomerization of CXCR4 impairs cancer cell growth and migration and sensitizes cancer cells for apoptosis.
CXCR4-targeting sdAbs are available at QVQ as labeled and unlabeled proteins.
